Wendi Young’s Post

View profile for Wendi Young, graphic

CEO at Triverity Laboratories

The comment period just ended for the recent Cannabis Species Inflorescence Proposed Draft Monograph from the USP. The newest proposed monograph tightened the range of THC and CBD to 90 - 110% of the labeled amount. This is in alignment with most drug products but could be a challenge with the inherent variability of plant material. Another change to the monograph is the addition of a second option for microbial limits. The second option has significantly tighter limits for at risk populations such as immunocompromised patients. Not sure if the intent is to label product for different patient populations. Curious to hear thoughts on how this would be implemented! https://lnkd.in/gfGE6F6p

Cannabis Species Inflorescence

Cannabis Species Inflorescence

hmc.usp.org

Kevin McKernan

CSO at Medicinal Genomics Corporation

5mo

Can they present any data on the health risks for TAC and TYM? I’m curious how the USP satisfies Kochs postulates with tests that never identify a pathogen from a beneficial microbe? Seems like they are picking numbers out of thin air? On the other hand one can measure a minimum infective dose of a specific species and prove pathogenicity of the isolated organism.

Like
Reply

To view or add a comment, sign in

Explore topics